Microsatellite Instability
Microsatellite Instability
Explore linked clinical trials. Standard reference: MESH:M049689014 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms, mismatch repair cancer syndrome 1 | Active, not recruiting | Phase 2 | 2026-10-08 | NCT03607890 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-09-25 | NCT06004245 | |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-09-21 | NCT07750158 | |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-09-11 | NCT04817826 | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Abdominal Neoplasms, Biliary Tract Neoplasms, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Epstein-Barr virus infection, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Male Urogenital Diseases, Microsatellite Instability, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, basal cell carcinoma, basal cell neoplasm, benign urinary system neoplasm, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, endometrium neoplasm, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, human papilloma virus infection, infectious disease, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, otorhinolaryngologic disease, polyomavirus infectious disease, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, sexually transmitted disease, skin disorder, skin neoplasm, small cell lung carcinoma, stomach disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, viral infectious disease, viral sexually transmitted disease, vulva cancer, vulvar disease | Recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT05592626 | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Infections, Microsatellite Instability, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, adenocarcinoma, adenoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, mesothelial neoplasm, mesothelioma, mismatch repair cancer syndrome 1, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, rectal disorder, sarcoma, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, viral infectious disease | Active, not recruiting | Phase 2 | 2026-06-01 | NCT03935893 | |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Genomic Instability, Microsatellite Instability, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Werner syndrome, hereditary disease, metabolic disease | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06898450 | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Infections, Liver Neoplasms, Male Urogenital Diseases, Microsatellite Instability, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, mismatch repair cancer syndrome 1, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, polyomavirus infectious disease, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, small cell lung carcinoma, squamous cell carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder, viral infectious disease | Active, not recruiting | Phase 2 | 2026-01-14 | NCT03228667 | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Anal Cancer, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Microsatellite Instability, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenoma, anal carcinoma, anus disorder, anus neoplasm, autosomal dominant Parkinson disease 4, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoid tumor, carcinoma, cervical carcinoma, cervix disorder, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, mesothelial neoplasm, mesothelioma, mouth disorder, neoplasm, neuroendocrine neoplasm, parotid disorder, parotid gland cancer, primitive neuroectodermal tumor, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland carcinoma, salivary gland disorder, small cell lung carcinoma, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, uterine disorder, vulva cancer, vulvar carcinoma, vulvar disease | Active, not recruiting | Phase 2 | 2025-09-22 | NCT02628067 | |
| National Cohort of Colorectal Cancers With Microsatellite Instability | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not stated | 2025-09-02 | NCT05511688 | |
| iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03350126 | |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 | |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, mismatch repair cancer syndrome 1, neoplasm | Not yet recruiting | Phase 2 | 2025-06-13 | NCT06646445 | |
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms, esophageal adenocarcinoma, gastric adenocarcinoma | Recruiting | Phase 2 | 2024-08-02 | NCT05177133 |